Observational analysis demonstrates altered brain energy metabolism in GLUT1-DS mice on ketogenic diet, suggesting clinical implications.
Motivation: The ketogenic diet is a first-line clinical treatment for glucose-transporter-1 deficiency syndrome (GLUT1-DS). Goal(s): To examine brain energy metabolism in a mouse model of GLUT1-DS by applying deuterium metabolic imaging (DMI) to mice fed either a normal diet (ND) or ketogenic diet (KD). Approach: Following administration of [6,6-2H2]glucose (Glc) or [3,4,4,4-2H4]β-hydroxybutyrate (βHB), employ DMI to evaluate GLUT1-DS mice and wild-type (WT) littermates on ND or KD. Results: The KD results in significant changes in levels of substrates Glc and βHB, and downstream metabolites, compared to the ND. Impact: DMI is directly clinically translatable. These results suggest it holds promise for quantification of the metabolic changes in GLUT1-DS patients, thereby relating these changes to the underlying pathophysiology, clinical symptoms and treatment efficacy in individual patients.
No takes yet. Share an insight, caveat, or question.
Garbow et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: